US15117B1035

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares

April 06, 2026 10:53 ET  | Source: Celldex Therapeutics, Inc. HAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics,…

7 days ago

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

March 27, 2026 10:30 ET  | Source: Celldex Therapeutics, Inc. - Improvements seen across all six DLQI Domains indicating broad,…

2 weeks ago

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease

March 01, 2026 09:45 ET  | Source: Celldex Therapeutics, Inc. - Late breaking Poster Presentation at AAAAI -- Ability to…

1 month ago